计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
R172598-5mg |
5mg | 现货 | | |
R172598-10mg |
10mg | 现货 | | |
R172598-25mg |
25mg | 现货 | | |
R172598-50mg |
50mg | 现货 | | |
R172598-100mg |
100mg | 现货 | | |
R172598-250mg |
250mg | 现货 | | |
R172598-1g |
1g | 现货 | |
别名 | 瑞博西林 |
---|---|
英文别名 | LEE-011;7-Cyclopentyl-N,N-dimethyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide |
规格或纯度 | 98% |
英文名称 | Ribociclib |
生化机理 | 双重cdk4 / cdk6抑制剂。诱导神经母细胞瘤细胞系(IC50 = 306 nM)的G1期细胞周期停滞和衰老。延迟体内肿瘤生长。口服具有生物活性。 |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
产品介绍 |
产品介绍: |
PubChem SID | 488201076 |
---|---|
IUPAC Name | 7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide |
INCHI | InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28) |
InChi Key | RHXHGRAEPCAFML-UHFFFAOYSA-N |
Canonical SMILES | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 |
PubChem CID | 44631912 |
分子量 | 434.5 |
溶解性 | 溶于DMSO, 最高浓度 (mg/mL): 4.35, 最高浓度(mM): 10 |
---|
象形图 |
Health Hazard Environmental Hazard |
---|---|
信号词 | Danger |
危险声明 |
H373: Causes damage to organs through prolonged or repeated exposure H411: Toxic to aquatic life with long lasting effects H360: May damage fertility or the unborn child |
预防措施声明 | P273,P280,P405,P501,P260,P391,P203,P318,P319 |
输入批号以搜索COA:
1. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M et al.. (2010) The landscape of somatic copy-number alteration across human cancers.. Nature, 463 (7283): (899-905). [PMID:20164920] |
2. Puyol M, Martín A, Dubus P, Mulero F, Pizcueta P, Khan G, Guerra C, Santamaría D, Barbacid M. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.. Cancer Cell, 18 (1): (63-73). [PMID:20609353] |
3. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. (2012) Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.. Cell Cycle, 11 (14): (2756-61). [PMID:22767154] |
4. Choi YJ, Li X, Hydbring P, Sanda T, Stefano J, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H et al.. (2012) The requirement for cyclin D function in tumor maintenance.. Cancer Cell, 22 (4): (438-51). [PMID:23079655] |
5. Sawai CM, Freund J, Oh P, Ndiaye-Lobry D, Bretz JC, Strikoudis A, Genesca L, Trimarchi T, Kelliher MA, Clark M et al.. (2012) Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia.. Cancer Cell, 22 (4): (452-65). [PMID:23079656] |
6. Zhang XH, Cheng Y, Shin JY, Kim JO, Oh JE, Kang JH. (2013) A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.. Cancer Biol Ther, 14 (7): (597-605). [PMID:23792647] |
7. Rader J, Russell MR, Hart LS, Nakazawa MS, Belcastro LT, Martinez D, Li Y, Carpenter EL, Attiyeh EF, Diskin SJ et al.. (2013) Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.. Clin Cancer Res, 19 (22): (6173-82). [PMID:24045179] |
8. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP et al.. (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.. N Engl J Med, 375 (18): (1738-1748). [PMID:27717303] |
9. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS et al.. (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.. Lancet Oncol, 19 (7): (904-915). [PMID:29804902] |
10. A-González N, Castrillo A. (2011) Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.. Biochim Biophys Acta, 1812 (8): (982-94). [PMID:21193033] |